News coverage about Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novelion Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.2076139335353 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of equities analysts have issued reports on NVLN shares. Royal Bank of Canada reiterated a “hold” rating and set a $9.00 price target on shares of Novelion Therapeutics in a research note on Tuesday, October 3rd. Zacks Investment Research downgraded Novelion Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 17th.
Novelion Therapeutics (NASDAQ NVLN) traded down $0.01 during trading on Thursday, hitting $4.07. 31,703 shares of the company’s stock traded hands, compared to its average volume of 60,525. Novelion Therapeutics has a 1 year low of $3.08 and a 1 year high of $12.12. The company has a debt-to-equity ratio of 6.53, a quick ratio of 1.28 and a current ratio of 1.45. The company has a market cap of $73.30, a PE ratio of -0.58 and a beta of 0.30.
Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.
Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.